# US 2014/0274953 A1 · Ex vivo human multiple myeloma cancer niche and its use as a model for personalized treatment of multiple myeloma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0274953 A1
- Document ID: US20140274953A1
- Status: Published application
- Kind: A1
- Application number: 13/827,170
- Filed: 2013-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: The Trustees of the Stevens Institute of Technology; Hackensack University Medical Center
- Inventors: Woo Lee; Jenny Zilberberg; David Samuel Siegel; Peter Tolias; Hongjun Wang; Wenting Zhang
- Web page: https://patentgrep.com/patent/US20140274953A1

## CPC

- C12N 5/0694: {Cells of blood, e.g. leukemia cells, myeloma cells}
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/575: for cancer
- G01N 2500/10: involving cells
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7028: Cancer
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.

## Claims

### Claim 1

An ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device comprising
(a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche comprising
(i) a mineralized bone-like tissue comprising (a) viable osteoblasts self-organized into cohesive multiple cell layers and (b) an extracellular matrix secreted by the viable adherent osteoblasts; and
(ii) a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and
(b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells, wherein
the human myeloma cells are in contact with osteoblasts of the BM niche, and
the viability of the human myeloma cells is maintained by the MM cancer niche.

### Claim 2 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device according to claim 1, wherein the biospecimen composition comprising mononuclear cells and the human myeloma cells further comprises human plasma autologous to the human myeloma cells.

### Claim 3 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device according to claim 1, wherein the microenvironment dynamically perfused by nutrients and dissolved gas molecules of the dynamic ex vivo bone marrow (BM) niche is suitable for dynamic propagation of the human myeloma cells.

### Claim 4 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche in a microfluidic device according to claim 1, wherein the MM niche further comprises osteoblast-secreted and MM cell-secreted soluble cytokines and growth factors.

### Claim 5 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the MM cells are adherent to osteoblasts of the BM niche.

### Claim 6 (depends on 5)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 5, wherein the MM cells adhere to the osteoblasts of the BM niche by cell-cell interaction.

### Claim 7 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the human myeloma cells are cellular components of a bone marrow aspirate.

### Claim 8 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the human myeloma cells are cellular components of peripheral blood.

### Claim 9 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the human myeloma cells are cellular components of a core biopsy.

### Claim 10 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the ex vivo dynamic multiple myeloma (MM) cancer niche is suitable for dynamic propagation of the human myeloma cells for at least 7 days.

### Claim 11 (depends on 1)

The ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 1, wherein the sample of human myeloma cells added to the BM niche constitutes 1×104 to 1×105 mononuclear cells.

### Claim 12 (depends on 1)

The ex vivo dynamic MM cancer niche according to claim 1, wherein propagation of the MM cells is capable of producing deterioration of the 3D ossified tissue of the BM niche.

### Claim 13

A method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche comprising
a. acquiring a biospecimen containing mononuclear cells from a subject in need thereof, wherein the biospecimen comprises viable multiple myeloma cells;
b. preparing a biospecimen composition comprising the viable multiple myeloma cells and plasma autologous to the subject;
c. preparing a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche comprising
(i) a mineralized bone-like tissue comprising (a) viable osteoblasts self-organized into cohesive multiple cell layers and (b) an extracellular matrix secreted by the viable adherent osteoblasts; and
(ii) a microenvironment dynamically perfused by nutrients and dissolved gas molecules;
d. adding the biospecimen composition to the three-dimensional tissue construct containing the dynamic ex vivo bone marrow (BM) niche to seed the BM niche with MM cells;
e. forming the dynamic ex vivo MM niche such that the MM cells are in contact with the osteoblasts of the BM niche, wherein the MM cancer niche is capable of maintaining viability of the human myeloma cells.

### Claim 14 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the MM niche further comprises osteoblast-secreted and MM cell-secreted soluble cytokines and growth factors.

### Claim 15 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the MM cells are adherent to osteoblasts of the BM niche.

### Claim 16 (depends on 15)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 15, wherein the MM cells adhere to the osteoblasts of the BM niche by cell-cell interaction.

### Claim 17 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the human myeloma cells are cellular components of a bone marrow aspirate.

### Claim 18 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the human myeloma cells are cellular components of peripheral blood.

### Claim 19 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the human myeloma cells are cellular components of a core biopsy.

### Claim 20 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the ex vivo dynamic multiple myeloma (MM) cancer niche is suitable for dynamic propagation of the human myeloma cells for at least 7 days.

### Claim 21 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein the sample of human myeloma cells added to the BM niche constitutes 1×104 to 1×105 mononuclear cells.

### Claim 22 (depends on 13)

The method for preparing an ex vivo dynamic multiple myeloma (MM) cancer niche according to claim 13, wherein propagation of the MM cells is capable of producing deterioration of the 3D ossified tissue of the BM niche.

### Claim 23

A method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject comprising:
a. acquiring a biospecimen from the subject, wherein the biospecimen comprises viable multiple myeloma cells;
b. preparing a biospecimen composition comprising the viable multiple myeloma cells and plasma autologous to the subject;
c. preparing a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche comprising
(i) a mineralized bone-like tissue comprising (a) viable osteoblasts self-organized into cohesive multiple cell layers and (b) an extracellular matrix secreted by the viable adherent osteoblasts; and
(ii) a microenvironment dynamically perfused by nutrients and dissolved gas molecules;
d. adding the biospecimen composition to the three-dimensional tissue construct containing the dynamic ex vivo bone marrow (BM) niche to seed the BM niche with MM cells;
e. forming the dynamic ex vivo MM niche such that the MM cells are in contact with the osteoblasts of the BM niche,
wherein the MM cancer niche is capable of maintaining viability of the human myeloma cells;
f. optionally cultivating the human myeloma cells in the MM cancer niche to propagate the MM cells for a period of time;
g. adding a test chemotherapeutic agent to the dynamic ex vivo MM niche comprising viable human myeloma cells;
h. comparing at least one of viability and level of apoptosis of the MM cells in the MM niche in the presence of the chemotherapeutic agent to an untreated control; and
i. initiating therapy to treat the MM in the patient if the agent significantly reduces viability or increases apoptosis of the MM cells.

### Claim 24 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, an antimetabolite, a natural product, a hormone, a biologic, a kinase inhibitor, a platinum coordination complex, an EDTA derivative, a platelet-reducing agent, a retinoid and a histone deacetylase inhibitor.

### Claim 25 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the chemotherapeutic agent is selected from the group consisting of an immunomodulatory drug, a proteasome inhibitor and a bisphosphonate.

### Claim 26 (depends on 25)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 25, wherein the immunomodulatory drug is Thalidomide or Lenalidomide.

### Claim 27 (depends on 25)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 25, wherein the proteasome inhibitor is Bortezomib.

### Claim 28 (depends on 25)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 25, wherein the bisphosphonate is Pamidronate or zoledronic acid.

### Claim 29 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the MM niche further comprises osteoblast-secreted and MM cell-secreted soluble cytokines and growth factors.

### Claim 30 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the MM cells are adherent to osteoblasts of the BM niche.

### Claim 31 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the MM cells adhere to the osteoblasts of the BM niche by cell-cell interactions.

### Claim 32 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the human myeloma cells are cellular components of a bone marrow aspirate.

### Claim 33 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the human myeloma cells are cellular components of peripheral blood.

### Claim 34 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the human myeloma cells are cellular components of a core biopsy.

### Claim 35 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the period of time for dynamic propagation of the human myeloma cells in the ex vivo dynamic MM cancer niche is at least 7 days.

### Claim 36 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein the sample of human myeloma cells added to the BM niche constitutes 1×104 to 1×105 mononuclear cells.

### Claim 37 (depends on 23)

The method for assessing chemotherapeutic efficacy of a chemotherapeutic agent on viable human multiple myeloma cells obtained from a subject according to claim 23, wherein propagation of the MM cells is capable of producing deterioration of the 3D ossified tissue of the BM niche.
